In an adequately powered, randomized controlled trial conducted over 2 years, the desired clinical outcome (i.e. prevention of a serious cardiovascular event) with a new drug is achieved in 25% of the study sample. In the patients who receive a placebo, only 15% obtain the same clinical benefit. The relative risk reduction achieved with the new drug over the study period is:
Lauran
3 months agoPearly
3 months agoMargret
3 months agoKenneth
4 months agoBernardine
4 months agoFrederica
4 months agoGail
4 months agoTamra
4 months agoCary
5 months agoGerardo
5 months agoNatalie
5 months agoDevorah
5 months agoDorathy
5 months agoPhyliss
5 months agoTambra
9 months agoSamuel
8 months agoAudry
8 months agoOzell
8 months agoMarg
8 months agoAltha
9 months agoJamal
10 months agoPamella
8 months agoXenia
9 months agoSkye
9 months agoDeonna
9 months agoElvis
10 months agoDenise
9 months agoJaclyn
9 months agoTimothy
9 months agoYuonne
10 months agoMalcolm
9 months agoKizzy
9 months agoAndrew
9 months agoOmega
9 months agoThea
10 months agoMelynda
10 months agoEllen
11 months agoDaren
11 months agoRuth
11 months ago